2020
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).
Morris M, Carroll P, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Gorin M, Siegel B. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). Journal Of Clinical Oncology 2020, 38: 5501-5501. DOI: 10.1200/jco.2020.38.15_suppl.5501.Peer-Reviewed Original ResearchPET/CTProstate cancerPrimary endpointOccult diseaseSystemic therapyLocal therapyClinical managementNovel PET imaging agentBiochemically recurrent prostate cancerDrug-related SAEsEquivocal conventional imagingMetastatic prostate cancerRecurrent prostate cancerMajority of ptsBCR prostate cancerCurrent imaging modalitiesPET imaging agentCommon AEsDefinitive therapySecondary endpointsPSA responseMulticenter studyLower PSAPCa cellsF-DCFPyLA prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.
Pouliot F, Carroll P, Probst S, Pienta K, Rowe S, Saperstein L, Siegel B, Patnaik A, Preston M, Alva A, Gorin M, Morris M. A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. Journal Of Clinical Oncology 2020, 38: 9-9. DOI: 10.1200/jco.2020.38.6_suppl.9.Peer-Reviewed Original ResearchHigh-risk prostate cancerF-DCFPyL PET/CTPET/CTRisk prostate cancerF-DCFPyLProstate cancerPositron emission tomographyM1 diseaseInitial stagingMetastatic lesionsPET/CT detection rateStandard cross-sectional imagingMetastasis detection rateDistant metastatic lesionsCT detection rateMetastatic prostate cancerCross-sectional imagingCurrent imaging modalitiesPositive predictive valueDetection rateEvaluable ptsPelvic LNsN1 diseaseMetastatic diseasePelvic LN
2019
Diagnostic performance of 18 F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).
Morris M, Durack J, Alva A, Vargas H, Piert M, Pachynski R, Pouliot F, Beauregard J, Preston M, Choudhury A, Saperstein L, Carroll P, Rowe S, Pienta K, Lin T, Wong V, Nichols M, Jensen J, Siegel B. Diagnostic performance of 18 F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18 F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC). Journal Of Clinical Oncology 2019, 37: 5012-5012. DOI: 10.1200/jco.2019.37.15_suppl.5012.Peer-Reviewed Original ResearchF-DCFPyL PET/CTMetastatic prostate cancerF-DCFPyL PET/CT scansPET/CTPositive predictive valuePET/CT scansProstate cancerF-DCFPyLPET imaging agentMulticenter studyCT scanNovel PET imaging agentHigh-risk prostate cancerDrug-related AEsDiagnostic performanceHigh positive predictive valueSoft tissue metastasesProstate-specific membrane antigenSite of diseaseImage-guided biopsyImaging agentDistant diseaseTissue metastasesCohort B.Patient managementA phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).
Morris M, Pouliot F, Saperstein L, Rowe S, Gorin M, Josephson D, Wong J, Carroll P, Lin T, Stambler N, Wong V, Jensen J, Siegel B. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). Journal Of Clinical Oncology 2019, 37: tps5093-tps5093. DOI: 10.1200/jco.2019.37.15_suppl.tps5093.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPET/CTRecurrent prostate cancerMetastatic prostate cancerProstate cancerF-DCFPyLPositron emission tomographyClinical impactDiagnostic performancePET/CT resultsEquivocal conventional imagingOpen-label studyWhole-body PET/CTProstate-specific membrane antigenYears of ageUnmet diagnostic needsEligible patientsF-fluciclovineDefinitive therapyBaseline PSAMulticenter studyDetection rateProstate adenocarcinomaPatient managementC-choline